CIP
CYTK icon

Chartwell Investment Partners’s Cytokinetics CYTK Stock Holding History

Chartwell Investment Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,013
Closed -$281K – 417
2024
Q1 		$281K Sell
4,013
-22,440
-85% -$1.74M 0.01% 405
2023
Q4 		$2.21M Buy
26,453
+2,950
+13% +$107K 0.08% 274
2023
Q3 		$692K Hold
23,503
– – 0.03% 374
2023
Q2 		$767K Buy
23,503
+1,142
+5% +$42.3K 0.03% 370
2023
Q1 		$787K Sell
22,361
-5,811
-21% -$237K 0.03% 363
2022
Q4 		$1.29M Buy
28,172
+1,598
+6% +$68.8K 0.05% 317
2022
Q3 		$1.29M Buy
26,574
+931
+4% +$44.8K 0.05% 318
2022
Q2 		$1.01M Buy
+25,643
New +$1.03M 0.04% 355
2020
Q4 		– Sell
-30,491
Closed -$660K – 431
2020
Q3 		$660K Buy
+30,491
New +$713K 0.02% 379

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Chartwell Investment Partners's CYTK Position: Q2 2024 in Review

Chartwell Investment Partners sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 4,013 shares — an estimated $281K sold.

Chartwell Investment Partners first reported a position in CYTK in Q3 2020 and held it in 9 quarters. The position peaked at $2.21M in Q4 2023. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Chartwell Investment Partners reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Chartwell Investment Partners sold 4,013 Cytokinetics shares in Q2 2024, an estimated $281K.
  • Chartwell Investment Partners first reported a position in Cytokinetics in Q3 2020 and held it in 9 quarters.
  • Chartwell Investment Partners's Cytokinetics position peaked at $2.21M in Q4 2023.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Chartwell Investment Partners's 13F filing for Q2 2024, filed 8 Aug 2024.